GW&K Investment Management LLC boosted its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,472,542 shares of the medical device company’s stock after buying an additional 19,336 shares during the period. Globus Medical makes up approximately 0.9% of GW&K Investment Management LLC’s portfolio, making the stock its 10th biggest position. GW&K Investment Management LLC’s holdings in Globus Medical were worth $110,294,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after acquiring an additional 328,217 shares in the last quarter. Sculptor Capital LP increased its holdings in shares of Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after acquiring an additional 58,000 shares in the last quarter. Boston Partners increased its holdings in shares of Globus Medical by 119.7% during the third quarter. Boston Partners now owns 3,415,554 shares of the medical device company’s stock valued at $255,898,000 after acquiring an additional 1,860,564 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Globus Medical by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after purchasing an additional 33,976 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Globus Medical by 14.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after purchasing an additional 225,534 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Globus Medical
In other news, Director James Tobin sold 41,666 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the sale, the director directly owned 15,000 shares in the company, valued at approximately $1,127,400. The trade was a 73.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 76,666 shares of company stock valued at $5,794,017. 18.38% of the stock is owned by insiders.
Globus Medical Trading Down 2.8%
Shares of NYSE GMED opened at $68.56 on Friday. The business has a 50-day moving average of $76.13 and a 200-day moving average of $82.29. The firm has a market capitalization of $9.08 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a 12 month low of $68.25 and a 12 month high of $101.40.
Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. During the same quarter in the previous year, the company earned $1.18 EPS. The business’s quarterly revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts predict that Globus Medical, Inc. will post 4.98 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on GMED shares. Canaccord Genuity Group cut their target price on Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, November 6th. UBS Group began coverage on shares of Globus Medical in a report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price objective on the stock. Truist Financial dropped their price objective on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 9th. BMO Capital Markets lowered shares of Globus Medical from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $94.00 to $78.00 in a research note on Friday, November 6th. Finally, Wells Fargo & Company boosted their price objective on Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $96.08.
Get Our Latest Research Report on GMED
About Globus Medical
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
See Also
- Five stocks we like better than Globus Medical
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
